FrancophonIA/ELRC3.0 huggingface dataset:
English: The review covered medicines authorised via national procedures in individual EU Member States, whose marketing authorisation applications included data from Semler's bioanalytical site (Semler Research Center Private Ltd, 75A, 15th Cross, 1st Phase, JP Nagar, Bangalore 560 078, Karnataka, India) and from Semler's clinical site (PA Arcade, #21, 22, 23, Kodigehali Main Road, Sahakaranagar Post, Bangalore 560 092, Karnataka, India).
Estonian: Läbivaatamine hõlmas ravimeid, mis olid riiklike menetlustega heaks kiidetud ELi üksikutes liikmesriikides ja mille müügiloa taotlused sisaldasid andmeid, mis olid saadud uurimiskeskuse Semler bioanalüüsilaborist (Semler Research Center Private Ltd, 75A, 15th Cross, 1st Phase, JP Nagar, Bangalore 560 078, Karnataka, India) ja Semleri kliinilisest laborist (PA Arcade, #21, 22, 23, Kodigehali Main Road, Sahakaranagar Post, Bangalore 560 092, Karnataka, India).
English: The list of medicines recommended to remain on the market can be found here.
Estonian: Ravimite loetelu, mille müügiluba soovitatakse alles jätta, on siin.
English: The review was carried out by the Committee for Medicinal Products for Human Use (CHMP), responsible for questions concerning medicines for human use, which has adopted the Agency's opinion.
Estonian: Läbivaatamise viis läbi inimravimite komitee, kes vastutab inimravimitega seotud küsimuste eest ja kes võttis vastu Euroopa Ravimiameti arvamuse.
English: • Patients should continue to take their medicines as prescribed and contact their doctors in case of questions or concerns.
Estonian: • Patsiendid peavad jätkama ravimite võtmist ettenähtud korras ning küsimuste tekkides peavad pöörduma oma arsti või apteekri poole.
English: On 21 July 2016, the European Medicines Agency (EMA) recommended suspending a number of nationally approved medicines for which bioequivalence studies were conducted at Semler Research Centre Private Ltd, Bangalore, India.
Estonian: 21. juulil 2016 soovitas Euroopa Ravimiamet (EMA) peatada mitme riiklikult heaks kiidetud ravimi müügiloa, mille bioekvivalentsusuuringud tehti Indias Bangalore'is asuvas uurimiskeskuses Semler Research Centre Private Ltd.
English: Semler is a contract research organisation (CRO) with an analytical and a clinical site located in Bangalore, India.
Estonian: Semler on lepinguline uurimisorganisatsioon, mille analüüsilabor ja kliiniline labor paikneb Indias Bangalore'is.
English: More about Semler
Estonian: Lisateave uurimiskeskuse Semler kohta
English: • A number of medicines for use in the EU rely on studies carried out at the Semler site in India.
Estonian: • Mitmed ELis kasutusel olevad ravimid toetuvad Indias uurimiskeskuses Semler tehtud uuringutele.
English: EMA's Committee for Medicinal Products for Human Use (CHMP) concluded that the studies conducted at Semler cannot be accepted in marketing authorisation applications in the EU.
Estonian: EMA inimravimite komitee järeldas, et Semleri tehtud uuringuid ei saa ELis müügilubade taotluste hindamisel aktsepteerida.
English: These sites conduct the analytical and clinical parts of bioequivalence studies, some of which are used to support marketing authorisation applications of medicines in the EU.
Estonian: Neis tehti bioekvivalentsusuuringute analüütilised ja kliinilised osad, millest mõnda kasutati ravimite müügilubade taotluste toetuseks ELis.
English: During the evaluation, alternative studies were provided for some of these medicines.
Estonian: Hindamise ajal esitati mõne kõnealuse ravimi kohta muudest allikatest pärinevaid uuringute andmeid.
English: No generic medicine authorised centrally via EMA was tested in these sites.
Estonian: Nendes keskustes ei olnud uuritud ühtegi tsentraalselt EMA kaudu heaks kiidetud geneerilist ravimit.
English: It also included ongoing marketing authorisation applications for medicines which use study data from these sites.
Estonian: Menetlus sisaldas ka hindamisel olevate ravimite müügilube, mille toetuseks kasutati nendes keskustes tehtud uuringute andmeid.
English: • There is currently no evidence of unexpected harm or lack of effectiveness with any medicine approved on the basis of studies conducted at Semler.
Estonian: • Uurimiskeskuses Semler tehtud uuringute põhjal heaks kiidetud ravimite ootamatu kahju või efektiivsuse puudumise kohta tõendeid praegu ei ole.
English: The findings from FDA and WHO inspections called into question the quality management system in place at Semler, and thus the reliability of the data of all bioequivalence studies, including those used to support marketing authorisation applications in the EU.
Estonian: FDA ja WHO kontrollkäikude tulemused tekitasid kahtlusi Semleri keskuses kasutatava kvaliteedijuhtimissüsteemi ja seega kõigi bioekvivalentsusuuringute, sh ELi müügilubade taotluste toetavate andmete usaldusväärsuse suhtes.
English: The Agency also recommended that medicines being evaluated for authorisation and which rely only on bioequivalence studies from this site should not be authorised until bioequivalence is demonstrated using alternative data.
Estonian: Amet soovitas mitte anda müügiluba ravimitele, mille hindamine on pooleli ja mis toetuvad ainult selles keskuses tehtud bioekvivalentsusuuringutele seni, kuni bioekvivalentsus ei ole tõendatud muudest allikatest pärit andmetega.
English: These studies show bioequivalence, and therefore, the CHMP recommended that these medicines can remain on the market.
Estonian: Need uuringud tõestasid bioekvivalentsust ja seega soovitas inimravimite komitee nende ravimite müügiload alles jätta.
English: • Medicines still under evaluation cannot be granted authorisation in the EU on the basis of studies conducted at Semler; further data would have to be provided to support authorisation.
Estonian: • Hindamisel olevatele ravimitele ei saa Semleris tehtud uuringute alusel müügiluba anda, müügiloa andmise toetuseks peab esitama lisaandmeid.
English: Thus, no medicines can be approved on the basis of these studies.
Estonian: Seega ei saa nende uuringute põhjal anda ühelegi ravimile müügiluba.
English: • Medicines that have been suspended can have their suspension lifted if the companies provide alternative data demonstrating bioequivalence.
Estonian: • Peatatud müügiloaga ravimite müügiloa saab taastada, kui ettevõtted esitavad bioekvivalentsust tõendavad muudest allikatest pärinevad andmed.
English: Bioequivalence studies usually form the basis for approval of generic medicines.
Estonian: Need bioekvivalentsuse uuringud on tavaliselt geneeriliste ravimite müügilubade andmise aluseks.
English: Bioequivalence studies performed at the site cannot be used to support medicines approval in the EU
Estonian: Selles keskuses tehtud uuringuid ei saa kasutada ravimite heakskiitmise toetuseks ELis.
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom22 September 2016 EMA/633693/2016
Estonian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom22.
English: EMA's review followed an FDA inspection1 that identified several issues at Semler's bioanalytical site, including the substitution and manipulation of subjects' clinical samples.
Estonian: EMA vaatas andmed läbi pärast USA toidu- ja ravimiameti (FDA) kontrollkäiku,1 milles tuvastati Semleri uurimiskeskuse bioanalüüsilaboris mitu probleemi, sh uuritavate kliiniliste proovide asendamine ja proovidega manipuleerimine.
English: The Semler site also performs bioequivalence studies for some medicines authorised in the US and medicines included in the WHO prequalification programme3.
Estonian: Ameerika Ühendriikides müügiluba omava ravimi ja WHO eelkvalifitseerimisprogrammi kaasatud ravimi bioekvivalentsusuuringuid3.
English: http://www.fda.gov/Drugs/DrugSafety/ucm495778.htm 2 http://apps.who.int/prequal/info_applicants/NOC/2016/NOC_Semler12April2016.pdf
Estonian: 2 http://apps.who.int/prequal/info_applicants/NOC/2016/NOC_Semler12April2016.pdf.
English: • Generic medicines containing abacavir/lamivudine (used to treat HIV), which were approved on the basis of studies conducted at Semler, can remain on the market in the EU.
Estonian: • Semleris tehtud uuringute põhjal heaks kiidetud abakaviiri/lamivudiini (kasutatakse HIV-nakkuse raviks) sisaldavad geneerilised ravimid võivad jääda ELi turule, sest läbivaatamise ajal esitati bioekvivalentsust tõendavad muudest allikatest pärinevad uuringutulemused.
English: The World Health Organization (WHO) also raised serious concerns2 regarding data integrity and manipulation of study samples following its own inspections of Semler's bioanalytical and clinical sites.
Estonian: Maailma Terviseorganisatsioon (WHO) tõstatas pärast omapoolset kontrollkäiku Semler uurimiskeskuse bioanalüüsilaborisse ja kliinilistesse laboritesse samuti tõsiseid küsimusi2 seoses andmete terviklikkusega ja uuringuproovidega manipuleerimisega.
English: • The bioequivalence studies performed at the Semler site have been found to be flawed, so they cannot be relied on. As a result, several medicines approved in the EU have been suspended.
Estonian: • Uurimiskeskuses Semler tehtud bioekvivalentsusuuringutes on tuvastatud vigu, mistõttu ei saa uuringuid pidada usaldusväärseiks.
English: 1 Article 29(2) of Directive 2001/83/EC, as amended.
Estonian: Direktiivi 2001/83/EÜ artikkel 29 lõige 2 ja selle muudatused.
English: The application was withdrawn in Germany, Norway and Spain, but the procedure was positively ended in all other Member States on 7 March 2003.
Estonian: Taotlus võeti tagasi Saksamaal, Norras ja Hispaanias, kuid kõigis teistes liikmesriikides lõpetati menetlus positiivselt 7. märtsil 2003.
English: International Non-Proprietary Name (INN): Rosuvastatin calcium
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): Rosuvastatin calcium
English: The Rapporteur and Co-Rapporteur appointed were Dr P. Nilsson and Dr. G. Calvo, respectively.
Estonian: Ettekandjaks ja kaasettekandjaks olid määratud vastavalt dr P. Nilsson ja dr G. Calvo.
English: The final opinion was converted into a Decision by the European Commission on 09 August 2005.
Estonian: See lõppotsus kinnitati Euroopa Komisjoni otsusena 9. augustil 2005.
English: The issue was referred for arbitration by the UK on 1 November 2004 (day 89).
Estonian: Küsimus suunati vahekohtumenetluseks Ühendkuningriigile 1. novembril 2004 (89. päeval).
English: This procedure started on 04 August 2004.
Estonian: Menetlust alustati 4. augustil 2004.
English: OPINION FOLLOWING AN ARTICLE 29(2)1 REFERRAL FOR Crestor 5 mg
Estonian: ARVAMUS PÄRAST ARTIKLI 29 LÕIKE 21 JÄRGSET ESILDIST Crestor 5 mg
English: On the basis of the marketing authorisation for Crestor (5 mg) granted by The Netherlands, on 21 July 2004 the applicant submitted an application for Mutual Recognition to 13 Concerned Member States.
Estonian: Crestorile (5 mg) Madalmaades antud müügiloa põhjal esitas taotleja 21. juulil 2004 vastastikuse tunnustamise taotluse 13 asjassepuutuvas liikmesriigis.
English: Written explanations were provided by the Marketing Authorisation Holder on 07 February 2005.
Estonian: Müügiloa hoidja esitas oma kirjalikud selgitused 7. veebruaril
English: The arbitration procedure started on 18 November 2004.
Estonian: Vahekohtumenetlus algas 18. novembril 2004.
English: The approved use in The Netherlands was a 5 mg start dose for patients with predisposing factors to myopathy, and 10 mg as the recommended start dose for patients without these predisposing factors.
Estonian: Heakskiidetud näidustuseks Hollandis oli 5 mg algannus patsientidele, kellel on eelsoodumus lihaspatoloogia tekkeks ja 10 algannus ilma sellise eelsoodumuseta patsientidele.
English: During its April 2005 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/risk ratio is favourable for Crestor 5 mg or Crestor 10 mg as start dose.
Estonian: Tuginedes kõigile esitatud andmetele ja komitee sisesele arutelule, jõudis inimtervishoius kasutatavate ravimite komitee oma 2005. aasta jaanuari koosolekul seisukohale, et Crestori 5 mg ja Crestori 10 mg algannuse riski ja kasu vahekord on soodne.
English: Crestor (rosuvastatin calcium) is a selective 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) that has been approved for use as a lipid-regulating agent in the management of patients with dyslipidaemia.
Estonian: Crestor (kaltsiumrosuvastatiin) on selektiivne 3-hüdroksü-3-metüülglutarüül-koensüümi A (HMG
English: As part of the marketing authorisation for rosuvastatin within Europe, AstraZeneca committed to apply for a 5-mg dose of rosuvastatin together with any necessary variations within 12 months of completion of the Mutual Recognition Process for the 10 mg, 20 mg and 40 mg formulations.
Estonian: 5 mg annuse kohta koos kõigi vajalike teisenditega 12 kuu jooksul alates 10, 20, ja 40 mg ravimvormide vastatikuse tunnustamise menetluse lõpetamisest.
English: Netherlands on 6 November 2002 and a Mutual Recognition Procedure was started on 7 December 2002.
Estonian: detsembril 2002 algatati vastastikuse tunnustamise menetlus.
English: Changes to SPC section 4.2 (Posology and method of administration) and 4.4 (Special warnings and special precautions for use) arising from the arbitration process were agreed by CHMP and a positive opinion was adopted on 21 April 2005.
Estonian: Vahekohtumenetlusest tulenevad muutused ravimi omaduste kokkuvõtte punktis 4.2 (Annustamine ja manustamisviis) ja 4.4
English: A Marketing Authorisation for Crestor (10 to 40 mg) was originally granted to AstraZeneca in The
Estonian: Crestori (10-40 mg) algne müügiluba anti AstraZenecale Madalmaades 6. novembril 2002, ning 7.
English: Not Recommended
Estonian: Ei soovitata
English: Due to poor enrolment, the study was terminated early and only 51 patients were randomized.
Estonian: Vähese kaasatuse tõttu lõpetati uuring varakult ning randomiseeriti vaid 51 patsienti.
English: From a microbiological point of view, the product should be used immediately.
Estonian: Mikrobioloogilisest seisukohast on oluline, et preparaati kasutataks kohe.
English: Other medicines and Cancidas
Estonian: Muud ravimid ja Cancidas
English: Do not use this medicine after the expiry date which is stated on the carton and the vial (the first two numbers are the month; the next four numbers are the year).
Estonian: Ärge kasutage seda ravimit pärast kõlblikkusaega, mis on märgitud karbil ja viaalil (esimesed kaks numbrit tähistavad kuud; järgnevad neli numbrit aastaarvu).
English: Your doctor will determine the duration of your treatment and how much Cancidas you will be given each day.
Estonian: Arst otsustab, kui kaua ravi kestab ja kui palju Cancidas't te iga päev saate.
English: Paediatric patients (12 months to 17 years)
Estonian: Lapsed (vanuses 12 kuud kuni 17 aastat)
English: Based on this study, no posology recommendations for neonates and infants can be made.
Estonian: Selle uuringu põhjal ei saa anda annustamissoovitusi vastsündinutele ja imikutele.
English: If this occurs, caspofungin should be discontinued and appropriate treatment administered.
Estonian: Kui see tekib, tuleb kaspofungiini kasutamine lõpetada ning alustada sobivat ravi.
English: 70 mg (from two 50 mg vials)**
Estonian: 70 mg (kahest 50 mg viaalist)**
English: This is because Cancidas can affect the way some other medicines work.
Estonian: Sest Cancidas võib mõjutada mõnede teiste ravimite toimet.
English: • if you are allergic to caspofungin or any of the other ingredients of this medicine (listed in section 6).
Estonian: - kui olete kaspofungiini või selle ravimi mis tahes koostisosade (loetletud lõigus 6) suhtes allergiline.
English: Cancidas will always be prepared and given to you by a healthcare professional.
Estonian: Cancidas'e valmistab ette ja manustab alati meditsiinitöötaja.
English: If you have been given more Cancidas than you should Your doctor will decide how much Cancidas you need and for how long each day.
Estonian: Kui teile manustatakse Cancidas't rohkem kui ette nähtud Teie arst otsustab, kui palju Cancidas't te vajate ja kui kaua iga päev.
English: • some HIV medicines such as efavirenz or nevirapine
Estonian: • mõned HIV-vastased ravimid, nagu nt efavirens ja nevirapiin;
English: In elderly patients (65 years of age or more), the area under the curve (AUC) is increased by approximately 30 %.
Estonian: Eakatel patsientidel (üle 65 eluaasta) suureneb kontsentratsiooni-aja kõvera alune pindala (AUC) ligikaudu 30%.
English: • Cancidas has not been studied in pregnant women.
Estonian: • Cancidas'e kasutamist rasedatel naistel ei ole uuritud.
English: 3 for 96 hours) and fever (>38.0°C) not responding to ≥96 hours of parenteral antibacterial therapy.
Estonian: 3 96 tundi) ja palavik (> 38,0°C), mis ei muutunud ≥ 96 tundi saadud parenteraalse antibakteriaalse ravi tulemusena.
English: Store in a refrigerator (2C to 8C).
Estonian: Hoida külmkapis (2C...8C).
English: Cancidas makes fungal cells fragile and stops the fungus from growing properly.
Estonian: Cancidas muudab seenerakud hapraks ja takistab seene korralikku kasvamist.
English: Pharmacotherapeutic group: antimycotics for systemic use, ATC Code: J02AX04
Estonian: Farmakoterapeutiline rühm: seenevastased ained süsteemseks kasutamiseks, ATC-kood: J02AX04
English: A small amount of caspofungin is excreted unchanged in urine (approximately 1.4 % of dose).
Estonian: Väike kogus kaspofungiini eritub muutumatul kujul uriiniga (umbes 1,4% annusest).
English: If you are worried that you may have been given too much Cancidas, tell your doctor or nurse straight away.
Estonian: Kui te olete mures, et teile on manustatud liiga palju Cancidas't, teatage sellest kohe oma arstile või meditsiiniõele.
English: Cancidas is used to treat the following infections in children, adolescents and adults:
Estonian: Cancidas't kasutatakse lastel, noorukitel ja täiskasvanutel järgmiste nakkuste raviks:
English: **If 70 mg vial is not available, the 70 mg dose can be prepared from two 50 mg vials.
Estonian: ** Kui 70 mg viaali ei ole võimalik kasutada, saab 70 mg annuse valmistada kahest 50 mg viaalist.
English: Do not use Cancidas
Estonian: Ärge kasutage Cancidas't
English: • serious fungal infections in your tissues or organs (called ‘invasive candidiasis').
Estonian: • tõsised seennakkused teie kudedes ja elundites (nimetatakse „invasiivseks kandidiaasiks“).
English: Only a trained healthcare professional who has read the complete directions should prepare the medicine (please see below “Instructions of how to reconstitute and dilute Cancidas”).
Estonian: Seda ravimit peab manustamiseks ette valmistama ainult vastava väljaõppe saanud meditsiinitöötaja, kes on läbi lugenud kogu juhendi (palun vt allpool „Cancidas'e lahustamise ja lahjendamise juhend”).
English: Each pack contains one vial of powder.
Estonian: Igas pakis on üks pulbri viaal.
English: DO NOT MIX OR CO-INFUSE CANCIDAS WITH ANY OTHER MEDICINES, as there are no data available on the compatibility of CANCIDAS with other intravenous substances, additives, or medicinal products.
Estonian: CANCIDAS't EI TOHI SEGADA EGA INFUNDEERIDA KOOS TEISTE RAVIMITEGA, kuna puuduvad andmed CANCIDAS'e sobivuse kohta teiste veenisiseselt manustatavate ainete, lisaainete või ravimpreparaatidega.
English: • cough, serious breathing difficulties - if you are an adult and have invasive aspergillosis you may be experiencing a serious respiratory problem that could result in respiratory failure.
Estonian: • köha, tõsised hingamisraskused - kui te olete täiskasvanu ja teil on invasiivne aspergilloos, võib teil olla tõsine hingamishäire, mis võib viia hingamispuudulikkuseni;
English: BSA (m2) X 70 mg/m2 = Loading Dose
Estonian: BSA (m2) X 70 mg/m2 = algannus
English: Also some other medicines can affect the way Cancidas works.
Estonian: Ka mõned teised ravimid võivad mõjutada Cancidas'e toimet.
English: What Cancidas looks like and contents of the pack Cancidas is a sterile, white to off-white compact powder.
Estonian: Kuidas Cancidas välja näeb ja pakendi sisu Cancidas on steriilne valge või valkjas kompaktne pulber.
English: Beta (1,3)-D-glucan is not present in mammalian cells.
Estonian: Beeta(1,3)-D-glükaani ei esine imetajarakkudes.
English: Very common: may affect more than 1 in 10 people:
Estonian: Väga sage - võib mõjutada rohkem kui ühte inimest 10st:
English: Cancidas may also cause Serious Cutaneous Adverse Reactions such as Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN).
Estonian: Cancidas võib põhjustada ka tõsiseid naha kõrvaltoimeid nagu Stevensi-Johnsoni sündroom (SJS) ja toksiline epidermise nekrolüüs (TEN).
English: • fungal infections in your nose, nasal sinuses or lungs (called ‘invasive aspergillosis') if other anti-fungal treatments have not worked or have caused side effects.
Estonian: • seennakkused teie ninas, ninakõrvalurgetes või kopsudes (nimetatakse „invasiivne aspergilloos“), kui teised seenevastased ravid ei ole mõjunud või on põhjustanud kõrvaltoimeid.
English: Caspofungin has in vitro activity against Aspergillus species (Aspergillus fumigatus [N = 75], Aspergillus flavus [N = 111], Aspergillus niger [N = 31], Aspergillus nidulans [N = 8], Aspergillus terreus [N = 52], and Aspergillus candidus [N = 3]).
Estonian: Kaspofungiinil on in vitro aktiivsus Aspergillus spp (Aspergillus fumigatus [N = 75], Aspergillus flavus [N = 111], Aspergillus niger [N = 31], Aspergillus nidulans [N = 8], Aspergillus terreus [N = 52] ja Aspergillus candidus [N = 3]) vastu.
English: Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands or
Estonian: Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, Holland või
English: Driving and using machines There is no information to suggest that Cancidas affects your ability to drive or operate machinery.
Estonian: Autojuhtimine ja masinatega töötamine Puuduvad andmed, mis viitaks, et Cancidas mõjutab autojuhtimise ja masinate käsitsemise võimet.
English: Patients with rare hereditary problems of fructose intolerance or sucrase-isomaltase insufficiency should not take this medicinal product (see section 2).
Estonian: Patsiendid, kellel esineb mõni haruldane pärilik suhkru ainevahetuse häire, näiteks fruktoositalumatus või sahharoosi-isomaltaasi puudulikkus, ei tohi seda ravimit kasutada (vt lõik 2).
English: Caspofungin also has in vitro activity against Candida species (Candida albicans [N = 1,032], Candida dubliniensis [N = 100], Candida glabrata [N = 151], Candida guilliermondii [N = 67], Candida kefyr [N = 62], Candida krusei [N = 147], Candida lipolytica [N = 20], Candida lusitaniae [N = 80], Candida parapsilosis [N = 215], Candida rugosa [N = 1], and Candida tropicalis [N = 258]), including isolates with multiple resistance transport mutations and those with acquired or intrinsic resistance to fluconazole, amphotericin B, and 5-flucytosine.
Estonian: Kaspofungiinil on ka in vitro aktiivsus Candida spp vastu (Candida albicans [N = 1032], Candida dubliniensis [N = 100], Candida glabrata [N = 151], Candida guilliermondii [N = 67], Candida kefyr [N = 62], Candida krusei [N = 147], Candida lipolytica [N = 20], Candida lusitaniae [N = 80], Candida parapsilosis [N = 215], Candida rugosa [N = 1]) ja Candida tropicalis [N = 258]), sealhulgas isolaadid multiresistentsuse transportmutatsioonidega ning omandatud või sisemise resistentsusega flukonasooli, amfoteritsiin B ja 5-flutsütosiini suhtes.
English: The most frequent diagnoses were bloodstream infections (candidaemia) (77 %, n = 186) and Candida peritonitis (8 %, n = 19); patients with Candida endocarditis, osteomyelitis, or meningitis were excluded from this study.
Estonian: Kõige sagedasemad diagnoosid olid vereringe infektsioonid (kandideemia) (77%, n = 186) ning Candida peritoniit (8%, n = 19); uuringusse ei kaasatud patsiente, kellel esines Candida endokardiit, osteomüeliit või meningiit.